Grade III Glioma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Grade III Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Not Applicable

Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

GlioblastomaWHO Grade III GliomaWHO Grade II Glioma
M.D. Anderson Cancer Center117 enrolled1 locationNCT04479696
Recruiting
Phase 2

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

GlioblastomaOligodendrogliomaWHO Grade III Glioma+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04623931
Recruiting
Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recurrent Diffuse Intrinsic Pontine GliomaDiffuse Intrinsic Pontine GliomaWHO Grade III Glioma+3 more
University of California, San Francisco360 enrolled32 locationsNCT05009992
Recruiting
Early Phase 1

Implantable Microdevice In Primary Brain Tumors

GlioblastomaAstrocytomaGrade II Glioma+5 more
Oliver Jonas12 enrolled1 locationNCT04135807
Recruiting
Not Applicable

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

GlioblastomaGrade III GliomaHigh-Grade Gliomas+1 more
Medical University of Warsaw35 enrolled2 locationsNCT06975332
Recruiting
Phase 1

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

GlioblastomaMalignant GliomaRecurrent Glioblastoma+3 more
Sabine Mueller, MD, PhD20 enrolled20 locationsNCT04323046
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974